Point-of-Care Diagnostics Market Size, Industry Trends, Growth and Forecast 2026-2034

According to IMARC Group, the global point-of-care diagnostics market Size reached USD 57.1 Billion in 2025 and is projected to reach USD 109.5 Billion by 2034, expanding at a CAGR of 7.27% during 2026-2034. This robust trajectory reflects rising clinical adoption, technological advancement, and the expanding global footprint of decentralized diagnostic testing.

Point of Care Diagnostics Industry Overview:

Point-of-care diagnostics encompass a broad category of testing devices and kits - including blood-glucose monitors, cardio-metabolic monitoring kits, pregnancy and fertility testing kits, infectious disease testing kits, cholesterol test strips, and hematology testing kits - designed to deliver rapid, accurate results outside traditional laboratory settings. These devices leverage biosensors, microfluidics, and increasingly AI-enabled analytics to streamline diagnosis and improve turnaround time.

Modern POC diagnostic platforms are enabling earlier disease detection, continuous chronic disease monitoring, and improved healthcare accessibility in remote and underserved regions. Cutting-edge devices now combine compact, portable form factors with expanded test menus and digital connectivity - addressing longstanding challenges around lab dependency and diagnostic turnaround time.

Key product categories shaping point of care diagnostics market share include:

• Blood-Glucose Monitoring Kits: User-friendly, portable devices enabling self-testing without specialized medical training - the leading product segment in 2025
• Cardio-Metabolic Monitoring Kits: Devices supporting continuous monitoring of cardiovascular and metabolic health indicators
• Pregnancy and Fertility Testing Kits: Widely adopted home-based testing solutions offering convenience and rapid results
• Infectious Disease Testing Kits: Rapid molecular and antigen-based tests critical for managing outbreaks and routine screening
• Cholesterol Test Strips: Compact testing tools supporting cardiovascular risk assessment at the point of care
• Hematology Testing Kits: Devices enabling rapid blood analysis outside centralized laboratory settings.

Global Market Overview & Point of Care Diagnostics Market Statistics:

Below are the key point of care diagnostics market statistics drawn from IMARC Group's comprehensive market analysis:

Base Year - 2025
Historical Period - 2020-2025
Forecast Period - 2026-2034
Market Size in 2025 - USD 57.1 Billion
Market Forecast in 2034 - USD 109.5 Billion
Market Growth Rate (2026-2034) - 7.27% CAGR
Largest Region - North America

Request for a Sample Report for Detailed Market Insights Evaluation: https://www.imarcgroup.com/point-of-care-diagnostics-market/requestsample

Key Market Drivers & Trends in 2026:

Several powerful forces are shaping point of care diagnostics market growth and driving expansion across global healthcare markets:

1. Growing Prevalence of Chronic and Infectious Diseases:

According to the World Health Organization (WHO), non-communicable chronic diseases kill 41 million people each year - equivalent to 74% of all deaths globally. Infectious diseases such as HIV also remain a major health challenge, with an estimated 39.0 million people living with HIV in 2022. This rising disease burden is significantly expanding demand for rapid, decentralized diagnostic solutions, driving sustained demand across hospitals, clinics, and home-care settings worldwide and strengthening overall point of care diagnostics market share.

2. Continuous Technological Advancements in Diagnostic Platforms:

Innovations in miniaturization, biosensors, and connectivity are creating smart, portable diagnostic devices capable of delivering laboratory-grade accuracy outside traditional settings. In February 2023, Huwel Lifesciences developed a portable RT-PCR device delivering results in about 30 minutes. Abbott's ID NOW, the world's fastest molecular POC test, delivers COVID-19 results in just 13 minutes. In May 2023, Danaher Corporation introduced the Dxl 9000 Access Immunoassay Analyzer, capable of running up to 215 tests per hour - innovations that are improving diagnostic accuracy and broadening clinical utility across procedures.

3. Rising Demand for Rapid and Home-Based Testing:

Patients and clinicians increasingly prefer rapid, convenient testing over traditional lab-based diagnostics. The accelerating demand for home-based and portable testing devices is propelling the point of care diagnostics market by facilitating greater patient convenience, particularly in remote and underserved regions where access to centralized laboratory facilities is limited.

4. Growing Emphasis on Personalized Medicine:

The increasing need for personalized medicine is propelling market growth. The National Cancer Institute (NCI) has launched a large-scale precision medicine cancer initiative, while WHO reported global health expenditure reached a new high of USD 9 Trillion in 2020 - about 11% of global GDP. POC diagnostics play a pivotal role in this shift, offering rapid and targeted diagnostic solutions that aid precise disease identification and monitoring.

5. Strategic Collaborations and Regulatory Support:

As of February 22, 2024, the FDA's Diagnostic Data Program launched an initiative supporting development of innovative methods for collecting, harmonizing, and analyzing diagnostic data from tests performed outside traditional laboratories. Strategic collaborations with federal agencies, such as NIH's ITAP and RADx programs, are facilitating authorization of at-home tests through standardized evaluation protocols - supporting continued point of care diagnostics market growth.

6. Increasing Investment in Healthcare Infrastructure:

Increased investments in healthcare infrastructure are significantly expanding access to sophisticated diagnostic solutions globally. Growing integration of AI and biosensors into diagnostics has streamlined testing processes, improving both accuracy and efficiency, and creating lucrative opportunities across emerging and developed markets alike.

Key Market Segmentation:

By Product Type:

Blood-Glucose Monitoring Kit - Largest Segment: Blood-glucose monitoring kits lead the market in 2025, owing to their user-friendly design, allowing patients to self-test without specialized medical training. Their compact, portable nature and broad accessibility - including in remote or underserved areas - continues to drive dominance within the point of care diagnostics market share landscape.

Cardio-Metabolic Monitoring Kit: Supports continuous monitoring of cardiovascular and metabolic health indicators, increasingly adopted for chronic disease management.

Pregnancy and Fertility Testing Kit: Widely adopted home-based testing solutions valued for convenience, privacy, and rapid results.

Infectious Disease Testing Kit: Critical for outbreak management and routine screening, with rapid molecular tests like Abbott's ID NOW driving strong segment growth.

Cholesterol Test Strip: Supports cardiovascular risk assessment through compact, easy-to-use testing tools.

Hematology Testing Kit: Enables rapid blood analysis outside centralized laboratory settings, supporting faster clinical decision-making.

By Platform, Prescription Mode & End-User:

The point of care diagnostics market is further segmented by platform (including immunoassay, molecular diagnostics, and microfluidics-based platforms), prescription mode (prescription-based and over-the-counter), and end-user (hospitals, home-care settings, diagnostic centres, and point-of-care clinics). Hospitals and home-care settings represent significant end-user segments, driven by high patient volumes and the accelerating shift toward decentralized, patient-centric testing.

Regional Market Analysis:

North America (Largest United States & Canada): advanced healthcare infrastructure, high prevalence of chronic and infectious diseases, strong regulatory support from the FDA, and robust demand for home-based and portable testing devices.

Europe: Germany, France, UK, Italy, Spain; mature healthcare systems, rising chronic disease burden, and strong investment in digital diagnostic technology.

Asia Pacific: China, Japan, India, South Korea, Australia; fast-expanding healthcare sector, rising infectious disease burden, growing medical tourism, and increasing diagnostic investment.

Latin America Brazil, Mexico; growing demand for advanced diagnostics driven by expanding healthcare infrastructure and rising chronic disease prevalence.

Middle East & Africa: UAE, Saudi Arabia, South Africa; healthcare modernization programs and rising demand for rapid, decentralized diagnostic solutions.

Connect for Detailed Segmentation Analysis - Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=2113&flag=C

Leading Players in the Point of Care Diagnostics Industry:

The global point of care diagnostics market features established diagnostics conglomerates alongside specialized device manufacturers.

Key companies profiled in the IMARC Group report include:

• Abbott Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Quidel Corporation
• Molbio Diagnostics
• Huwel Lifesciences

The report includes competitive analysis covering market structure, player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant assessing point-of-care diagnostics market share dynamics among leading players.

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302

This release was published on openPR.